Skip to main content
Equibles
TYRA logo

TYRA · Tyra Biosciences, Inc.

Track TYRA — free

Use TYRA with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about TYRA

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$26.05 +0.36 (+1.40%) At close · Aug 21
Market Cap
$1.55B
Shares
59.68M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$26.05 Open$25.95 Day$25.95–26.81 52W close$11.70–39.61 Avg vol 30d594K Short int9.2M · 15.5% float · 17.8d Short vol67% Last earningsAug 4, 2026 DataSep 2021–Aug 2026 Filing10-Q · Aug 4

Up next

Next earnings call
Dec 21, 2026 Est · unconfirmed · in 17 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 4, 2026

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Bullish Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 15.1 · calm Equity put/call 0.58
Technical
price trend
Strong Sell
50 / 200-day cross Death cross
Price vs 200-day avg −12%
below
Price vs 50-day avg −12%
below
RSI (14) 40
neutral
MACD trend Negative
52-week position 51%
mid-range
Momentum
relative strength
Very Weak
1-month return −15%
trailing
6-month return −20%
trailing
YTD return −1%
this year
Relative strength −31%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) Death cross
50d $30 › 200d $30 — 200d above 50d
Institutional flow Accumulating
+4% holders QoQ · +33 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
15.49% of float · ▼ -6.9% MoM · 17.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
171 holders — near 3-yr high, broad support
Squeeze score 65
elevated · 0–100
Fundamentals
Weak
EPS growth −33%
Y/Y
Free cash flow $-95.3M
Balance sheet $77.4M
net cash
Quant / Vol
risk profile
Very High
Volatility 62%
annualized · 1-yr
Max drawdown −37%
past year
ATR 6.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 2 · 0
50 / 200-day cross
Death cross Bearish
Price vs 200-day avg
−12% Bearish
Price vs 50-day avg
−12% Bearish
RSI (14)
40 Neutral
MACD trend
Negative Bearish
52-week position
51% Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) Death cross
50d $30 › 200d $30 — 200d above 50d
Institutional flow Accumulating
+4% holders QoQ · +33 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
15.49% of float · ▼ -6.9% MoM · 17.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
171 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $12 Now $26 · 51% Range high $40
vs 200-day avg -12% vs 50-day avg -12% 50-day below 200-day death cross

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Cash, Cash Equivalents and Short-Term Investments $383.5M Q1 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
TYRA
Tyra Biosciences, Inc.
this stock
$1.55B -0.9% — — 15.5%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $136.93B +20.9% +46.2% 31.5 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $85.87B +8.1% +20.8% 20.7 3.3%
ARGX
Argenx SE
 $64.56B +23.6% — — 2.1%
CSLLY
Csl Ltd
 $58.31B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
171
% held
117.0%
Net QoQ
+3.4M sh
Top holder
RA CAPITAL MANAGEMENT, L.…
Held Float
View
Held by Funds
Fund positions
179
View
Short & Settlement
Short Interest Falling
Shares short
9.2M
Days to cover
17.8d
Change
-683.8K sh
View
Short Volume
Short vol %
67%
As of
Aug 21, 2026
Short Total
View
Fails to Deliver
FTD shares
536
Value
$17.7K
As of
Jul 31, 2026
View
Off-Exchange
Off-exchange %
35.6%
Week of
Jul 13, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-119.9M
EPS diluted
$-2.01
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 4, 2026
This year
12
View
Proposed Sales
Value
$2.0M
Shares
53.2K
Filed
Mar 26, 2026
View
Exempt Offerings
Offering
$200.0M
Filed
Feb 13, 2024
View
Earnings & Events
Earnings Calls
Last call
Aug 4, 2026
View

Performance

5D 20D 120D MTD YTD
TYRA +3.0% -15.0% -19.9% -18.3% -0.9%
SPY -1.4% +3.6% +11.6% +2.5% +12.3%
vs SPY +4.4% -18.6% -31.5% -20.8% -13.2%
Key facts CIK 1863127 CUSIP 90240B106 13F (30d) 165 filings 163 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)